Gilead Sciences, Inc. announced that the company’s Marketing Authorization Application (MAA) for tenofovir alafenamide (as fumarate) (TAF) 25 mg an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infectionhas been fully validated and is now under assessment by the European Medicines Agency (EMA).